Condition: Parkinson Disease · Multiple System Atrophy, Parkinson Variant · Progressive Supranuclear Palsy · Sponsor: University of Florida
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| University of California San Diego | La Jolla, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Augusta University | Augusta, Georgia, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| University of Chicago | Chicago, Illinois, United States | — |
| University of Kentucky | Lexington, Kentucky, United States | — |
| Johns Hopkins University | Lutherville, Maryland, United States | — |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | — |
| Massachusetts General Hospital | Charlestown, Massachusetts, United States | — |
+ 9 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.